Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 11, 2005, Pages 4721-4732

  Dorr, Patrick ^a,b   Westby, Mike ^a   Dobbs, Susan ^a   Griffin, Paul ^a   Irvine, Becky ^a   Macartney, Malcolm ^a   Mori, Julie ^a   Rickett, Graham ^a   Smith Burchnell, Caroline ^a   Napier, Carolyn ^a   Webster, Rob ^a   Armour, Duncan ^a   Price, David ^a   Stammen, Blanda ^a   Wood, Anthony ^a   Perros, Manos ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UK 107 543; UK 427 857; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; EMBRYO; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS STRAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CYCLOHEXANES; DOGS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HELA CELLS; HIV-1; HUMANS; MALE; MEMBRANE FUSION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CCR5; TRIAZOLES;

EID: 27644510382     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.11.4721-4732.2005     Document Type: Article

References (56)

1. Adkison, K. K., A. Shachoy-Clark, L. Fang, Y. Lou, K. O'Mara, M. M. Berrey, and S. C. Piscitelli. 2005. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrob. Agents Chemother. 49:2802-2806.
2. Barber, C. G. 2004. CCR5 antagonists for the treatment of HIV. Curr. Opin. Investig. Drugs 5:851-861.
3. Beatty, C., M. Bradley, D. Brambilla, F. Breakenridge, J. W. Bremer, J. Dargavon, B. Ladd, D. Livnatt, C. Michel, C. Mundy, V. Price, T. Ramacciotti, P. Reichelderfer, B. Staes, C. Starkey, and M. Winters. 1997. DAIDS Virology Manual for HIV Laboratories, p. 73-76. Division of Acquired Immunodeficiency Syndrome, NIAID, NIH, Bethesda, Md.
4. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
5. Bradley, J., J. Gill, F. Bertelli, S. Letafat, R. Corbau, P. Hayter, P. Harrison, A. Tee, W. Keighley, M. Perros, G. Ciaramella, A. Sewing, and C. Williams. 2004. Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry. J. Biomol. Screen 9:516-524.
6. Bruhl, H., J. Cihak, M. Stangassinger, D. Schlondorff, and M. Mack. 2001. Depletion of CCRS-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV. J. Immunology. 166:2420-2426.
7. Chen, R. Y., J. M. Kilby, and M. S. Saag. 2002. Enfuvirtide. Expert Opin. Investig. Drugs 11:1837-1843.
8. Cocchi, F., A. L. DeVico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
9. Cole, K. E., C. A. Strick, T. J. Paradis, K. T. Ogborne, M. Loetscher, R. P. Gladue, W. Lin, J. G. Boyd, B. Moser, D. E. Wood, B. G. Sahagan, and K. Neote. 1998. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187:2009-2021.
10. Combadiere, C., S. K. Ahuja, H. L. Tiffany, and P. M. Murphy. 1996. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J. Leukoc. Biol. 60:147-152.
11. De Clercq, E. 1999. The emerging role of fusion inhibitors in HIV infection. Drugs R&D 2:321-331.
12. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, and S. J. O'Brien. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:1856-1862.
13. Erratum, Science 274:1069.
14. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, Z. Zhang, W. A. O'Brien, L. Ratner, G. M. Shaw, and E. Hunter. 2001. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virology. 75:8605-8614.
15. Dobbs, S., M. Perros, and G. A. Rickett. July 2001. An assay method for determining whether an agent is capable of modulating the interaction of CCR5 with gp120. Patent EP1118858.
16. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
17. Guo, Q., H. T. Ho, I. Dicker, L. Fan, N. Zhou, J. Friborg, T. Wang, B. V. McAuliffe, H. G. Wang, R. E. Rose, H. Fang, H. T. Scarnati, D. R. Langley, N. A. Meanwell, R. Abraham, R. J. Colonno, and P. F. Lin. 2003. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 77:10528-10536.
18. Ickovics, J., and C. Meade. 2002. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care 14:309-318.
19. Jansson, C. C., K. Pohjanoksa, J. Lang, S. Wurster, J. M. Savola, and M. Scheinin. 1999. alpha(2)-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. Eur. J. Pharmacol. 374:137-146.
20. Kazmierski, W. M., L. Boone, W. Lawrence, C. Watson, and T. Kenakin. 2002. CCR5 chemokine receptors: gatekeepers of HIV-1 infection. Curr. Drug Targets Infect. Disord. 2:265-278.
21. Kutilek, V. D., D. A. Sheeter, J. H. Elder, and B. E. Torbett. 2003. Is resistance futile? Curr. Drug Targets Infect. Disord. 3:295-309.
22. Lin, P. F., W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y. F. Gong, H. G. Wang, R. Rose, G. Yamanaka, B. Robinson, C. B. Li, R. Fridell, C. Deminie, G. Deniers, Z. Yang, L. Zadjura, N. Meanwell, and R. Colonno. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 100:11013-11018.
23. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
24. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
25. Mack, M., B. Luckow, P. J. Nelson, J. Cihak, G. Simmons, P. R. Clapham, N. Signoret, M. Marsh, M. Stangassinger, F. Borlat, T. N. Wells, D. Schlondorff, and A. E. Proudfoot. 1998. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187:1215-1224.
26. Maeda, K., H. Nakata, Y. Koh, T. Miyakawa, H. Ogata, Y. Takaoka, S. Shibayama, K. Sagawa, D. Fukushima, J. Moravek, Y. Koyanagi, and H. Mitsuya. 2004. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78:8654-8662.
27. Maeda, K., K. Yoshimura, S. Shibayama, H. Habashita, H. Tada, K. Sagawa, T. Miyakawa, M. Aoki, D. Fukushima, and H. Mitsuya. 2001. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 276:35194-35200.
28. Meanwell, N. A., and J. F. Kadow. 2003. Inhibitors of the entry of HIV into host cells. Curr. Opin. Drug Discov. Dev. 6:451-461.
29. Mosier, D. E., G. R. Picchio, R. J. Gulizia, R. Sabbe, P. Poignard, L. Picard, R. E. Offord, D. A. Thompson, and J. Wilken. 1999. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73:3544-3550.
30. Mueller, A., N. G. Mahmoud, M. C. Goedecke, J. A. McKeating, and P. G. Strange. 2002. Pharmacological characterization of the chemokine receptor, CCR5. Br. J. Pharmacol. 135:1033-1043.
31. Novak, E. J., A. W. Liu, G. T. Nepom, and W. W. Kwok. 1999. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Investig. 104:R63-R67.
32. O'Brien, S. J., and J. P. Moore. 2000. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177:99-111.
33. Owen, S. M., D. Rudolph, D. Schols, N. Fujii, N. Yamamoto, and R. B. Lal. 2002. Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds. J. Med. Virol. 68:147-155.
34. Parkin, N. T., N. S. Hellmann, J. M. Whitcomb, L. Kiss, C. Chappey, and C. J. Petropoulos. 2004. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:437-443.
35. Pasi, K. J., C. A. Sabin, P. V. Jenkins, H. L. Devereux, C. Ononye, and C. A. Lee. 2000. The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. Br. J. Haematol. 111:136-142.
36. Paterlini, M. G. 2002. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys. J. 83:3012-3031.
37. Peltonen, J. M., M. Pihlavisto, and M. Scheinin. 1998. Subtype-specific stimulation of [S-35]Gtp-gamma-S binding by recombinant alpha(2)-adrenoceptors. Eur. J. Pharmacol. 355:275-279.
38. Perrin, L., L. Kaiser, and S. Yerly. 2003. Travel and the spread of HIV-1 genetic variants. Lancet Infect. Dis. 3:22-27.
39. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
40. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100:4144-4149. (First published 18 March 2003; 10.1073/pnas.0630530100.)
41. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
42. Scozzafava, A., A. Mastrolorenzo, and C. T. Supuran. 2002. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J. Enzyme Inhibition Med. Chem. 17:69-76.
43. Seibert, C., and T. P. Sakmar. 2004. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr. Pharm. Des. 10:2041-2062.
44. Strizki, J. M., S. Xu, N. E. Wagner, L. Wojcik, J. Liu, Y. Hou, M. Endres, A. Palani, S. Shapiro, J. W. Clader, W. J. Greenlee, J. R. Tagat, S. McCombie, K. Cox, A. B. Fawzi, C. C. Chou, C. Pugliese-Sivo, L. Davies, M. E. Moreno, D. D. Ho, A. Trkola, C. A. Stoddart, J. P. Moore, G. R. Reyes, and B. M. Baroudy. 2001. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98:12718-12723.
45. Tagat, J. R., S. W. McCombie, D. Nazareno, M. A. Labroli, Y. Xiao, R. W. Steensma, J. M. Strizki, B. M. Baroudy, K. Cox, J. Lachowicz, G. Varty, and R. Watkins. 2004. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4- (trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. 47:2405-2408.
46. Tanaka, H., T. Minoshima, and N. Endo. 1995. The effect of a synthetic 7-thiaprostaglandin E1 derivative, TEI-6122, on monocyte chemoattractant protein-1 induced chemotaxis in THP-1 cells. Br. J. Pharmacol. 116:2298-2302.
47. Taylor, J. M., Y. Wang, L. Ahdieh, J. S. Chmiel, R. Detels, J. V. Giorgi, R. Kaslow, L. Kingsley, and J. Margolick. 2000. Causal pathways for CCR5 genotype and HIV progression. J. Acquir. Immune Defic. Syndr. 23:160-171.
48. Trkola, A., S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. Xu, L. Wojcik, J. Tagat, A. Palani, S. Shapiro, J. W. Clader, S. McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 99:395-400.
49. Tsou, C. L., R. P. Gladue, L. A. Carroll, T. Paradis, J. G. Boyd, R. T. Nelson, K. Neote, and I. F. Charo. 1998. Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor. J. Exp. Med. 188:603-608.
50. Volberg, W. A., B. J. Koci, W. Su, J. Lin, and J. Zhou. 2002. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302:320-327.
51. Watson, C., S. Jenkinson, W. Kazmierski, and T. Kenakin. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67:1268-1282. (First published 11 January 2005; 10.1124/mol.104.008565.)
52. Winters, M. A, J. M. Schapiro, J. Lawrence, and T. C. Merigan. 1998. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J. Virol. 72:5303-5306.
53. Yerly, S., L. Kaiser, E. Race, J. P. Bru, F. Clavel, and L. Perrin. 1999. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354:729-733.
54. Yerly, S., S. Vora, P. Rizzardi, J. P. Chave, P. L. Vernazza, M. Flepp, A. Telenti, M. Battegay, A. L. Veuthey, J. P. Bru, M. Rickenbach, B. Hirschel, and L. Perrin. 2001. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 15:2287-2292.
55. Zhang, Y., B. Lou, R. B. Lal, A. Gettie, P. A. Marx, and J. P. Moore. 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74:6893-6910.
56. Zhou, Y., T. Kurihara, R. P. Ryseck, Y. Yang, C. Ryan, J. Loy, G. Warr, and R. Bravo. 1998. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160:4018-4025.